BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 33945801)

  • 1. Synthesis of 16β-derivatives of 3-(2-bromoethyl)-estra-1,3,5(10)-trien-17β-ol as inhibitors of 17β-HSD1 and/or steroid sulfatase for the treatment of estrogen-dependent diseases.
    Lespérance M; Roy J; Djiemeny Ngueta A; Maltais R; Poirier D
    Steroids; 2021 Aug; 172():108856. PubMed ID: 33945801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new nonestrogenic steroidal inhibitor of 17β-hydroxysteroid dehydrogenase type I blocks the estrogen-dependent breast cancer tumor growth induced by estrone.
    Ayan D; Maltais R; Roy J; Poirier D
    Mol Cancer Ther; 2012 Oct; 11(10):2096-104. PubMed ID: 22914440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a non-estrogenic irreversible inhibitor of 17β-hydroxysteroid dehydrogenase type 1 from 3-substituted-16β-(m-carbamoylbenzyl)-estradiol derivatives.
    Maltais R; Ayan D; Trottier A; Barbeau X; Lagüe P; Bouchard JE; Poirier D
    J Med Chem; 2014 Jan; 57(1):204-22. PubMed ID: 24328103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
    Laplante Y; Cadot C; Fournier MA; Poirier D
    Bioorg Med Chem; 2008 Feb; 16(4):1849-60. PubMed ID: 18035543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First Dual Inhibitors of Steroid Sulfatase (STS) and 17β-Hydroxysteroid Dehydrogenase Type 1 (17β-HSD1): Designed Multiple Ligands as Novel Potential Therapeutics for Estrogen-Dependent Diseases.
    Salah M; Abdelsamie AS; Frotscher M
    J Med Chem; 2017 May; 60(9):4086-4092. PubMed ID: 28406629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical Synthesis and Biological Evaluation of 3-Substituted Estrone/Estradiol Derivatives as 17β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors Acting via a Reverse Orientation of the Natural Substrate Estrone.
    Ngueta AD; Roy J; Maltais R; Poirier D
    Molecules; 2023 Jan; 28(2):. PubMed ID: 36677690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer.
    Purohit A; Tutill HJ; Day JM; Chander SK; Lawrence HR; Allan GM; Fischer DS; Vicker N; Newman SP; Potter BV; Reed MJ
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):199-203. PubMed ID: 16414180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insight into the mode of action and selectivity of PBRM, a covalent steroidal inhibitor of 17β-hydroxysteroid dehydrogenase type 1.
    Trottier A; Maltais R; Ayan D; Barbeau X; Roy J; Perreault M; Poulin R; Lagüe P; Poirier D
    Biochem Pharmacol; 2017 Nov; 144():149-161. PubMed ID: 28800957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic profile of PBRM in rodents, a first selective covalent inhibitor of 17β-HSD1 for breast cancer and endometriosis treatments.
    Maltais R; Trottier A; Roy J; Ayan D; Bertrand N; Poirier D
    J Steroid Biochem Mol Biol; 2018 Apr; 178():167-176. PubMed ID: 29248731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual Targeting of Steroid Sulfatase and 17β-Hydroxysteroid Dehydrogenase Type 1 by a Novel Drug-Prodrug Approach: A Potential Therapeutic Option for the Treatment of Endometriosis.
    Mohamed A; Salah M; Tahoun M; Hawner M; Abdelsamie AS; Frotscher M
    J Med Chem; 2022 Sep; 65(17):11726-11744. PubMed ID: 35993890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An irreversible inhibitor of 17β-hydroxysteroid dehydrogenase type 1 inhibits estradiol synthesis in human endometriosis lesions and induces regression of the non-human primate endometriosis.
    Poirier D; Nyachieo A; Romano A; Roy J; Maltais R; Chai D; Delvoux B; Tomassetti C; Vanhie A
    J Steroid Biochem Mol Biol; 2022 Sep; 222():106136. PubMed ID: 35691460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New development in intracrinology of breast carcinoma.
    Sasano H; Suzuki T; Nakata T; Moriya T
    Breast Cancer; 2006; 13(2):129-36. PubMed ID: 16755106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical synthesis of C3-oxiranyl/oxiranylmethyl-estrane derivatives targeted by molecular modeling and tested as potential inhibitors of 17β-hydroxysteroid dehydrogenase type 1.
    Lespérance M; Barbeau X; Roy J; Maltais R; Lagüe P; Poirier D
    Steroids; 2018 Dec; 140():104-113. PubMed ID: 30273695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of fused 16β,17β-oxazinone-estradiol derivatives as a new family of non-estrogenic 17β-hydroxysteroid dehydrogenase type 1 inhibitors.
    Maltais R; Trottier A; Delhomme A; Barbeau X; Lagüe P; Poirier D
    Eur J Med Chem; 2015 Mar; 93():470-80. PubMed ID: 25728028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crucial Role of 3-Bromoethyl in Removing the Estrogenic Activity of 17β-HSD1 Inhibitor 16β-(m-Carbamoylbenzyl)estradiol.
    Maltais R; Ayan D; Poirier D
    ACS Med Chem Lett; 2011 Sep; 2(9):678-681. PubMed ID: 21927646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent Dual Inhibitors of Steroid Sulfatase and 17β-Hydroxysteroid Dehydrogenase Type 1 with a Suitable Pharmacokinetic Profile for
    Salah M; Tahoun M; Rudzitis-Auth J; Stotz L; van Koppen CJ; Laschke MW; Abdelsamie AS; Frotscher M
    J Med Chem; 2023 Jul; 66(13):8975-8992. PubMed ID: 37369108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxybenzothiazoles as new nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1).
    Spadaro A; Negri M; Marchais-Oberwinkler S; Bey E; Frotscher M
    PLoS One; 2012; 7(1):e29252. PubMed ID: 22242164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of substituted 15β-alkoxy estrone derivatives and their cofactor-dependent inhibitory effect on 17β-HSD1.
    Herman BE; Kiss A; Wölfling J; Mernyák E; Szécsi M; Schneider G
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1271-1286. PubMed ID: 31307240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dydrogesterone (Duphaston) and its 20-dihydro-derivative as selective estrogen enzyme modulators in human breast cancer cell lines. Effect on sulfatase and on 17beta-hydroxysteroid dehydrogenase (17beta-HSD) activity.
    Chetrite GS; Thole HH; Philippe JC; Pasqualini JR
    Anticancer Res; 2004; 24(3a):1433-8. PubMed ID: 15274306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Biophysical Chemistry Reveals a New Covalent Inhibitor with a Low-Reactivity Alkyl Halide.
    Li T; Maltais R; Poirier D; Lin SX
    J Phys Chem Lett; 2018 Sep; 9(18):5275-5280. PubMed ID: 30148957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.